Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
The alternating sequential administration of the NS and GemOx regimens may be a novel approach for first-line chemotherapy in patients with advanced PDAC requiring further study (ClinicalTrials.gov Identifier: ChiCTR1900024867).
Authors
- Tongsen Zheng (ORCID: https://orcid.org/0000-0002-7539-3924)
- Zhigang Ma (ORCID: https://orcid.org/0009-0008-1968-7822)
- Changjie Lou (ORCID: https://orcid.org/0000-0001-8729-1418)
- Yuandi Dong
- Haibo Lu (ORCID: https://orcid.org/0000-0001-6837-3530)
- Hongzhen Tang (ORCID: https://orcid.org/0000-0003-2146-7868)
- Hengzhen Li (ORCID: https://orcid.org/0000-0002-1140-3660)
- Yanqiao Zhang (ORCID: https://orcid.org/0000-0002-6206-8364)
- Na Li (ORCID: https://orcid.org/0000-0002-5627-6079)
- Zhiwei Li (ORCID: https://orcid.org/0009-0006-2550-7686)
- Guangyu Wang (ORCID: https://orcid.org/0000-0001-7679-540X)
- Dan Jiang (ORCID: https://orcid.org/0000-0002-9187-7152)
- Chao Zhan (ORCID: https://orcid.org/0000-0001-5732-8857)
- Qingwei Li (ORCID: https://orcid.org/0000-0002-1957-4464)
- Xiaona Fan
- Haitao Xu
- Chunhui Zhang (ORCID: https://orcid.org/0009-0000-8298-029X)
- Dan Wang (ORCID: https://orcid.org/0000-0001-7789-6747)
- Zhuo Chen (ORCID: https://orcid.org/0000-0001-6453-0447)
- Chao Liu (ORCID: https://orcid.org/0000-0002-6708-4654)
Institutions
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1093/oncolo/oyae207
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Harbin Medical University Cancer Hospital
- National Natural Science Foundation of China